1. Is there any policy to ensure the medical expenses of patients diagnosed in novel coronavirus?
Answer: After the medical expenses incurred by the diagnosed novel coronavirus patients are paid by the basic medical insurance, serious illness insurance and medical assistance according to the regulations, the personal burden will be subsidized by the finance and comprehensive protection will be implemented.
2. What are the policies for reimbursement of medical expenses for suspected patients, and what are the provisions for reimbursement of expenses for continuing hospitalization after excluding suspected patients?
A: The medical insurance payment policy for confirmed patients is implemented for suspected patients. After the suspected patients are excluded, the hospitalization expenses still need to continue, and the medical insurance reimbursement policy for confirmed patients continues to be implemented. All expenses will be settled at the time of discharge.
3. Does the patient need personal payment in advance?
A: For novel coronavirus patients, we should insist on emergency treatment and special treatment, and open a green channel for medical insurance. No matter whether you are insured, referred or transferred to a hospital, whether you can go through the formalities of medical treatment in different places, and whether you can settle online in different places, you will settle after the diagnosis and treatment. The medical insurance fund will pay the expenses first, and individuals do not need to pay in advance.
4. What are the provisions of medical insurance on drugs and medical services used by patients? What is the specific reimbursement policy?
A: Drugs and medical services used by patients in novel coronavirus are all included in the scope of medical insurance fund payment if they meet the diagnosis and treatment plan formulated by the health department. Among them, if the drugs and medical treatment items within the scope of medical insurance catalogue have temporarily cancelled the scope of payment, the reimbursement ratio shall be implemented according to the original medical insurance policy; Drugs and medical treatment items outside the scope of the catalogue are temporarily included in the scope of medical insurance payment, and the proportion of individual pays for medical treatment items is zero first, and drugs are reimbursed according to Class A. Drugs and medical treatment items that are clinically necessary but not included in the medical treatment plan are managed according to the medical insurance payment policy of drugs and medical treatment items in the medical treatment plan.
5. Does the new medical service for treating novel coronavirus patients need approval, and how to determine the specific price? How to realize medical insurance settlement payment?
A: The newly-added medical services for treating novel coronavirus patients during the epidemic period can be directly determined and used by designated medical institutions without going through the procedures for establishing new projects. The specific price is determined by itself according to the principle of cost calculation and pricing, and it is not allowed to deviate from the excessive cost pricing. By the medical insurance agencies into the medical insurance settlement system, given the settlement code, medical institutions corresponding settlement.
6. During the epidemic, is the self-made Chinese medicine medical insurance allowed to be used in the province reimbursed?
A: During the epidemic, the self-made preparations of traditional Chinese medicine approved by the Provincial Drug Administration and the Provincial Health and Wellness Committee were included in the scope of medical insurance payment, and the specific reimbursement ratio was determined by the municipalities according to the relevant regulations of local self-made preparations.
7. Can drugs and medical consumables needed for epidemic prevention and control be purchased offline?
A: During the epidemic, a green channel will be opened for purchasing drugs and medical consumables needed for epidemic prevention and control. Designated medical institutions can make emergency purchases offline, directly contact the production enterprises, and reasonably determine the purchase price according to the principle of fairness to ensure the clinical needs of medical institutions.
8. How to grasp the medical insurance regulations for patients with chronic diseases to relax long-term prescriptions during the epidemic?
A: In order to reduce the risk of cross-infection caused by patients going to and from the hospital many times, during the epidemic prevention and control period, for patients with chronic diseases such as hypertension and diabetes who are in stable condition and need to take fixed drugs for a long time, the dose can be relaxed to 3 months according to the needs of chronic diseases and the norms of diagnosis and treatment, but patients should take the medicine according to the doctor's advice. For some chronic diseases, the prescription of Chinese herbal pieces can be relaxed to two weeks. Necessary drugs for discharge can also be appropriately relaxed according to the needs of the disease.
9. Due to the epidemic situation, flexible employees and urban and rural residents can't handle the insurance payment business on schedule. Can you allow an extension?
A: Relax the time limit for flexible employees and urban and rural residents to pay medical insurance premiums. Failing to handle the insurance payment in time, it is allowed to pay back within 3 months after the end of the epidemic, which does not affect the insured's enjoyment of treatment.
10. Is the cost of consumables such as protective equipment used by medical staff reimbursed by medical insurance?
A: According to Document No.2 [2020] of the Ministry of Finance of People's Republic of China (PRC), the funds required for the procurement of special equipment for prevention and treatment and rapid diagnostic reagents for medical and health institutions to carry out epidemic prevention and control work shall be arranged by the local finance and subsidized by the central finance as appropriate.